Abstract Submissions
Satellite Symposia

Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®, LLC and Pharmacy Times Continuing Education. Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this live activity for a maximum of 26.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 26.75 Contact Hours.


Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). This activity is approved for a maximum of 22.75 contact hours under the ACPE universal activity numbers:

November 7, 2018, Conference Day 1 – 0290-9999-18-099-L01-P (7.75 contact hours)

November 8, 2018, Conference Day 2 – 0290-9999-18-100-L01-P (7.0 contact hours)

November 9, 2018, Conference Day 3 – 0290-9999-18-101-L01-P (8.0 contact hours)

The activity is available for continuing education (CE) credit through December 9, 2018.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Daiichi Sankyo, Inc., Eisai, Exelixis, Inc., Genomic Health, Inc., Ferring Pharmaceuticals, Inc., Incyte Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation, Novocure, Pfizer, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron, Seattle Genetics, Inc., Takeda Oncology, and Taiho Oncology, Inc.

36th Annual CFS®: Innovative Cancer Therapy for Tomorrow

36th Annual CFS®: Innovative Cancer Therapy for Tomorrow

Click to Register for 2020

Wednesday, November 7, 2018 – Friday, November 9, 2018
New York Marriott Marquis
1535 Broadway

New York, NY 10036
(800) 843-4898



Click Here to watch highlights from the 35th Annual CFS®

Founded in 1968 by
The Chemotherapy Foundation


click to View Brochure and Agenda

Rapid changes continue to occur in the management of solid and hematologic malignancies. Just this past year, practice-changing diagnostic, therapeutic, and supportive care strategies have entered clinical practice, and many more are poised to enter the field. Improved outcomes are achievable across multiple lines of care with the application of optimized testing approaches, locoregional and systemic therapies, targeted therapies, immunotherapies, and multimodal strategies. Critical knowledge and competence gaps among practitioners must be addressed to ensure that these approaches are effectively and safely integrated into practice. Each year, the Chemotherapy Foundation Symposium® (CFS®), brings together more than 2000 healthcare professionals for 3 days, with the aim of promoting the delivery of evidence-based, state-of-the-art cancer care for routine and the most challenging clinical scenarios. At the 36th Annual CFS®, our internationally renowned faculty will provide expert insights on the latest developments in cancer therapeutics, offering oncology practitioners an unparalleled opportunity to learn how innovative approaches fit into existing treatment paradigms to optimize care and outcomes for their patients with cancer.

Benefits of Attending

  • Incorporate the latest clinical data into your practice
  • Challenge the experts with your most difficult cases
  • Network with the top minds in oncology
  • 100 Experts. 25 Tumor Types. 3 Days. 1 Meeting.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Daiichi Sankyo, Inc., Eisai, Exelixis, Inc., Genomic Health, Inc., Ferring Pharmaceuticals, Inc., Incyte Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation, Novocure, Pfizer, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron, Seattle Genetics, Inc., Takeda Oncology, and Taiho Oncology, Inc.

Target Audience:

This educational activity is directed toward oncologists, hematologists, nurses, nurse practitioners, and pharmacists interested in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other healthcare professionals interested in the treatment of cancer are also invited to attend.

Learning Objectives:

Upon completion of this activity, participants should be better prepared to:

  • Determine the most appropriate testing strategies to identify molecular marker and treatment targets while stratifying risk to inform clinical decision-making in cancer management
  • Describe key practice-changing clinical trial results that inform appropriate diagnostic and treatment approaches for patients with hematologic malignancies and solid tumors
  • Identify evidence-based immunotherapeutic, chemotherapeutic, and targeted treatment strategies to optimize clinical outcomes
  • Delineate implementation strategies for multidisciplinary teams to anticipate and proactively manage treatment-related toxicities
  • Review and apply practice-changing evidence presented at major conferences and apply these findings to optimize the care of patients with cancer

2018 Hot Topics

  • Immunotherapies and Their Latest Applications in Cancer
  • Harnessing the Latest Technologies, Biomarkers, and Tests to Optimize Clinical Decision Making
    • Pan-Tumor Testing to Guide Treatment Planning
    • Expanded Applications of Precision Medicine
  • Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapy
  • Chemotherapy Versus Modern Agents: How to Get the Most Out of Available Therapies
  • Focused Update on Rare Hematologic Malignancies: Waldenström Macroglobulinemia and Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Does Chemotherapy Improve Outcomes in Early-Stage High-Risk Uterine Cancer?
  • State-of-the-Art Care for Patients With Melanoma: Sequencing, Triplet Combinations, Adjuvant Therapy, and Immunotherapy Selection
  • Evolving Treatment Paradigms in Lung Cancer: New Agents, New Indications, New Assays
  • Targeted and immunotherapeutic strategies for RCC and Bladder Cancer
  • PARP Inhibitor-Based Therapy for Breast and Gynecologic Cancers
  • Fertility Preservation in Premenopausal Women With Breast Cancer
  • Evidence-Based Management Updates Across All Breast Cancer Subtypes
  • Who Should Receive Extended Adjuvant Hormone Therapy for Breast Cancer?
  • Improving Outcomes Through Optimized Adverse Event Management
  • New Agents, New Opportunities, and New Clinical Questions in Gastrointestinal Cancers
  • Updates in Glioblastoma Multiforme; Head, Neck, and Thyroid Cancers; and Sarcoma
  • 2018 Special Focus: Patient-Centered Care and Oncology Practice: CINV, Pain Management, Neutropenia, Direct-to-Consumer Testing, and Next-Generation Sequencing
  • Back by Popular Demand: Nursing and How I Do It tracks and Medical Crossfire® debates
  • And Much More!

Program Co-Chairs

Adam M. Brufsky, MD, PhD
Professor of Medicine
Associate Chief, Division of Hematology/ Oncology
Co-Director, Comprehensive Breast Cancer Center Associate
Director, Clinical Investigation
University of Pittsburgh
Pittsburgh, PA

Benjamin Levy, MD
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC

William K. Oh, MD
Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
Associate Director of Clinical Research
The Tisch Cancer Institute
New York, NY

Committee Members

Arjun V. Balar, MD
Assistant Professor of Medicine
Director, Genitourinary Medical Oncology Program
Perlmutter Cancer Center, NYU Langone
New York, NY

Susana M. Campos, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

Ajai Chari, MD
Associate Professor
Medicine, Hematology, and Medical Oncology
The Mount Sinai Hospital
New York, NY

Alexander Drilon, MD
Clinical Director, Early Drug Development Service
Assistant Attending Physician, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Cathy Eng, MD, FACP
Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
Director, Department of Gastrointestinal Medical Oncology, Network Clinical Research
Associate Medical Director, Colorectal Center, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Jason J. Luke, MD, FACP
Assistant Professor of Medicine
The University of Chicago Medicine
Chicago, IL

John Mascarenhas, MD
Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Tisch Cancer Institute, Division of Hematology/Oncology
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, NY


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

In case of onsite emergency:

Professional Information


Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19

I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventive measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities, including providing proof at check in of being 2 weeks removed from receiving a full COVID-19 vaccination or results from a negative COVID-19 viral test taken no more than 3 days prior to the program.

I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.

* By checking this box, you have read and understand the above and agree to its terms.

Calendar of Events
Filter By